Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790933 · ClinicalTrials.gov registry record · Phase 3
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,243
- Enrollment target
NCT00790933 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 2,243 participants.
The verdict
NCT00790933, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,243 participants
- Enrollment target
Study Summary
The purpose of this multicenter, open-label study is to collect data on the occurrence of important clinical safety events resulting from chronic vedolizumab (MLN0002) administration.
Interventions
- DRUG Vedolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,243 participants |
| Start Date | 2009-05-22 |
| Est. Completion | 2017-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00790933
The ClinicalTrials.gov registry entry for NCT00790933 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vedolizumab is the first listed.
NCT00790933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00790933 about?
NCT00790933 is a clinical study titled "An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease". The purpose of this multicenter, open-label study is to collect data on the occurrence of important clinical safety events resulting from chronic vedolizumab (MLN0002) administration.
What is the current status of trial NCT00790933?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,243 participants. The study started on 2009-05-22. Estimated completion is 2017-10-31.
What interventions are being tested in trial NCT00790933?
The interventions under investigation include: Vedolizumab (DRUG).
Who is sponsoring clinical trial NCT00790933?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.